Answers are grounded in this paper and cite their sources.
Cancer drug shortages delay treatment, worsen patient outcomes and can cause significant stress to patients, healthcare providers and caregivers.1–4 Furthermore, they increase drug costs and the economic burden on patients.5 According to the Food and Drug Administration in the USA, 122 drugs out of 138 are facing shortage issues, involving 16 cancer drugs, at the time of writing this paper.6 Similarly, IQVIA, a leading data analytics platform, reported that cancer drug shortages have been significantly increasing since 2020 in the USA.7 Cisplatin, methotrexate, capecitabine and carboplatin were reported as facing shortage issues between March and June 2023.7 Drug shortages are also an issue within paediatric oncology practices,8 leading paediatricians to advocate for increased pharmaceutical production and strategical distribution.9 Several factors responsible for drug shortages are highlighted in the literature, of which the major one is the low price and profit margin of generic drugs, as well as supply and demand issues.5 10 11 Several studies have proposed both immediate and long-term strategies to mitigate cancer drug shortages. These include stockpiling adequate quantities of chemotherapy drugs, promoting the use and prescribing of generics, ensuring greater transparency from pharmaceutical companies regarding drug origins and standards and improving communication between healthcare professionals (HCPs) … Correspondence to Nabin Pathak; pathaknabin89{at}gmail.com
No takes yet. Share an insight, caveat, or question.
Pathak et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: